Publications by authors named "Stephen Calabro"
Background: Comparing effectiveness of biologics in real-world settings will help inform treatment decisions.
Objectives: We sought to compare therapeutic responses among patients initiating infliximab, adalimumab, or etanercept versus ustekinumab during the Psoriasis Longitudinal Assessment and Registry (PSOLAR).
Methods: Proportions of patients achieving a Physician Global Assessment score of clear (0)/minimal (1) and mean decrease in percentage of body surface area with psoriasis were evaluated at 6 and 12 months.
Background: Safety surveillance is needed for biologic therapies for psoriasis.
Objective: To assess the risk of adverse events of special interest (AEoSIs) with ustekinumab and other psoriasis treatments in a real-world setting using 2014 Psoriasis Longitudinal Assessment and Registry (PSOLAR) data. AEoSIs included malignancy (excluding nonmelanoma skin cancer), major adverse cardiovascular events (MACE), serious infection, and all-cause mortality.
Importance: The efficacy of treatment for psoriasis must be balanced against potential adverse events.
Objective: To determine the effect of treatment on the risk of serious infections in patients with psoriasis.
Design, Setting, And Participants: A multicenter, longitudinal, disease-based registry (Psoriasis Longitudinal Assessment and Registry [PSOLAR]) at dermatology centers.
Safety observations in 12095 patients with psoriasis enrolled in an international registry (PSOLAR): experience with infliximab and other systemic and biologic therapies.
J Drugs Dermatol
December 2014
Article Synopsis
- The study called PSOLAR looks at how safe certain medicines are for treating psoriasis, especially focusing on serious side effects over a long period of time.
- They found that older patients and those with past health issues had a higher chance of getting serious side effects like heart problems and infections.
- The results showed that while infliximab (a type of medicine) didn’t increase the risk of death or serious health problems, it was linked to a higher risk of serious infections.
The above-referenced article has been voluntarily withdrawn by the authors in order to present more updated data in a subsequent manuscript. The full Elsevier Policy on Article Withdrawal can be found at http://www.elsevier.
View Article and Find Full Text PDFBackground: Treatment with tumor necrosis factor (TNF)-α antagonists is effective in patients with moderate-to-severe plaque psoriasis, including those with impaired health-related quality of life (HRQoL).
Methods: PSUNRISE is a multicenter, open-label, prospective study evaluating the efficacy and safety of switching from etanercept to infliximab in psoriasis patients with an inadequate response to etanercept. Patients received intravenous infusions of infliximab 5 mg/ kg at weeks 0, 2, 6, 14, and 22.
Background: In patients with psoriasis and inadequate response (IR) to tumor necrosis factor-α antagonist treatment, the incremental benefit of switching to another tumor necrosis factor-α antagonist is unknown.
Objective: We sought to evaluate the clinical response to an etanercept-to-infliximab switch in patients with psoriasis and IR to etanercept.
Methods: Adults with moderate-to-severe plaque psoriasis and IR to etanercept (≥ 4 months) were eligible for this open-label study (called PSUNRISE).